

Ricardo C T Aguiar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6602566/publications.pdf>

Version: 2024-02-01

28
papers

4,536
citations

361413

20
h-index

501196

28
g-index

28
all docs

28
docs citations

28
times ranked

6088
citing authors

#	ARTICLE	IF	CITATIONS
1	Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. <i>Nature Medicine</i> , 2002, 8, 68-74.	30.7	2,217
2	Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. <i>Blood</i> , 2005, 105, 1851-1861.	1.4	778
3	MicroRNAs miR-125a and miR-125b constitutively activate the NF- κ B pathway by targeting the tumor necrosis factor alpha-induced protein 3 (<i>TNFAIP3</i>). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 7865-7870.	7.1	305
4	Targeting of SMAD5 links microRNA-155 to the TGF- β 2 pathway and lymphomagenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 3111-3116.	7.1	198
5	The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma. <i>Blood</i> , 2005, 105, 308-316.	1.4	141
6	Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas. <i>Clinical Cancer Research</i> , 2016, 22, 2301-2310.	7.0	136
7	Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib. <i>Blood</i> , 2003, 102, 4187-4190.	1.4	118
8	Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma. <i>Blood</i> , 2009, 113, 6681-6690.	1.4	71
9	IDH Mutation, Competitive Inhibition of FTO, and RNA Methylation. <i>Cancer Cell</i> , 2017, 31, 619-620.	16.8	65
10	D2HGDH regulates alpha-ketoglutarate levels and dioxygenase function by modulating IDH2. <i>Nature Communications</i> , 2015, 6, 7768.	12.8	64
11	MicroRNA 155 Control of p53 Activity Is Context Dependent and Mediated by Aicda and Socs1. <i>Molecular and Cellular Biology</i> , 2015, 35, 1329-1340.	2.3	54
12	A phosphodiesterase 4B-dependent interplay between tumor cells and the microenvironment regulates angiogenesis in B-cell lymphoma. <i>Leukemia</i> , 2016, 30, 617-626.	7.2	48
13	A capture-sequencing strategy identifies IRF8, EBF1, and APRIL as novel IGH fusion partners in B-cell lymphoma. <i>Blood</i> , 2013, 122, 726-733.	1.4	44
14	MicroRNA-155 controls RB phosphorylation in normal and malignant B lymphocytes via the noncanonical TGF- β 1/SMAD5 signaling module. <i>Blood</i> , 2014, 123, 86-93.	1.4	42
15	Rational combined targeting of phosphodiesterase 4B and SYK in DLBCL. <i>Blood</i> , 2009, 113, 6153-6160.	1.4	37
16	Gene Set Enrichment Analysis Unveils the Mechanism for the Phosphodiesterase 4B Control of Glucocorticoid Response in B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2011, 17, 6723-6732.	7.0	34
17	MicroRNA-155 expression and outcome in diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2009, 144, 138-140.	2.5	31
18	Safety and Pharmacodynamics of the PDE4 Inhibitor Roflumilast in Advanced B-cell Malignancies. <i>Clinical Cancer Research</i> , 2017, 23, 1186-1192.	7.0	25

#	ARTICLE	IF	CITATIONS
19	Tenovin-6 inhibits proliferation and survival of diffuse large B-cell lymphoma cells by blocking autophagy. <i>Oncotarget</i> , 2017, 8, 14912-14924.	1.8	24
20	Phosphodiesterase 4 inhibitors have wide-ranging activity in B-cell malignancies. <i>Blood</i> , 2016, 128, 2886-2890.	1.4	20
21	Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3K γ in Mature B-cell Malignancies. <i>Clinical Cancer Research</i> , 2018, 24, 1103-1113.	7.0	18
22	Regulation of PD-L1 expression is a novel facet of cyclic-AMP-mediated immunosuppression. <i>Leukemia</i> , 2021, 35, 1990-2001.	7.2	15
23	The tumor suppressor TMEM127 regulates insulin sensitivity in a tissue-specific manner. <i>Nature Communications</i> , 2019, 10, 4720.	12.8	14
24	MYC Regulation of D2HGDH and L2HGDH Influences the Epigenome and Epitranscriptome. <i>Cell Chemical Biology</i> , 2020, 27, 538-550.e7.	5.2	14
25	Biology Informs Treatment Choices in Diffuse Large B Cell Lymphoma. <i>Trends in Cancer</i> , 2017, 3, 871-882.	7.4	8
26	MYC, mitochondrial metabolism and O-GlcNAcylation converge to modulate the activity and subcellular localization of DNA and RNA demethylases. <i>Leukemia</i> , 2022, 36, 1150-1159.	7.2	8
27	Generation and characterization of the E μ -Irf8 mouse model. <i>Cancer Genetics</i> , 2020, 245, 6-16.	0.4	5
28	Cyclic AMP signalling, MYC and hypoxia-inducible factor 1 intersect to regulate angiogenesis in B-cell lymphoma. <i>British Journal of Haematology</i> , 2022, , .	2.5	2